Annexon, Inc. (ANNX)
NASDAQ: ANNX · Real-Time Price · USD
4.970
-0.280 (-5.33%)
At close: Aug 28, 2026, 4:00 PM EDT
5.01
+0.04 (0.80%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Annexon Employees
Annexon had 92 employees as of June 30, 2026. The number of employees decreased by 11 or -10.68% compared to the same quarter last year.
Employees
92
Change
-11
Growth
-10.68%
Revenue / Employee
n/a
Profits / Employee
-$2,202,913
Market Cap
942.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 92 | -11 | -10.68% |
| Mar 31, 2026 | 93 | -13 | -12.26% |
| Dec 31, 2025 | 96 | -4 | -4.00% |
| Sep 30, 2025 | 99 | 15 | 17.86% |
| Jun 30, 2025 | 103 | 32 | 45.07% |
| Mar 31, 2025 | 106 | 36 | 51.43% |
| Dec 31, 2024 | 100 | 29 | 40.85% |
| Sep 30, 2024 | 84 | 8 | 10.53% |
| Jun 30, 2024 | 71 | -6 | -7.79% |
| Mar 31, 2024 | 70 | -10 | -12.50% |
| Dec 31, 2023 | 71 | -9 | -11.25% |
| Sep 30, 2023 | 76 | -7 | -8.43% |
| Jun 30, 2023 | 77 | 2 | 2.67% |
| Mar 31, 2023 | 80 | 17 | 26.98% |
| Dec 31, 2022 | 80 | 19 | 31.15% |
| Sep 30, 2022 | 83 | 21 | 33.87% |
| Jun 30, 2022 | 75 | 18 | 31.58% |
| Mar 31, 2022 | 63 | 15 | 31.25% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Wave Life Sciences | 317 |
| Geron | 258 |
| Olema Pharmaceuticals | 150 |
| Cybin | 100 |
| Lexicon Pharmaceuticals | 81 |
| Design Therapeutics | 55 |
| Candel Therapeutics | 55 |
ANNX News
- 13 days ago - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Annexon participates in a conference call with JPMorgan - TheFly
- 13 days ago - Annexon reports Q2 EPS (28c), consensus (24c) - TheFly
- 13 days ago - Annexon expands Phase 3 ARCHER II trial - TheFly
- 13 days ago - Annexon upgraded to Market Perform from Underperform at Citizens - TheFly
- 18 days ago - Annexon Earnings Call Transcript: Q2 2026 - Transcripts
- 18 days ago - Annexon Earnings release: Q2 2026 - Filings
- 18 days ago - Annexon Quarterly report: Q2 2026 - Filings